We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Genfit (GNFT) EUR0.25

Sell:€2.98 Buy:€3.00 Change: €0.06 (1.97%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: €0.06 (1.97%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: €0.06 (1.97%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Contact details

Parc Eurasante 885 avenue Eugene Avinee
+33 (3) 20164000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€139.32 million
Shares in issue:
45.78 million
Euronext Paris
Euronext Next 150

Key personnel

  • Jean-Francois Mouney
    Chairman of the Board
  • Pascal Prigent
    Chief Executive Officer
  • Thomas Baetz
    Chief Financial Officer
  • Dean Hum
    Chief Operating Officer
  • Nathalie Huitorel
    Executive Vice President, Chief Administrative Officer
  • Stefanie Magner
    Chief Compliance Officer, Vice President - International Legal Affairs
  • Carol Addy
    Chief Medical Officer
  • Pascal Caisey
    Chief Commercial Officer
  • Suneil Hosmane
    Head of Global Diagnostics
  • Jean-Christophe Marcoux
    Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.